187 related articles for article (PubMed ID: 4015950)
1. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
Dowsett M; Santner SJ; Santen RJ; Jeffcoate SL; Smith IE
Br J Cancer; 1985 Jul; 52(1):31-5. PubMed ID: 4015950
[TBL] [Abstract][Full Text] [Related]
2. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
4. The role of aromatase inhibitors in breast cancer.
Powles TJ
Semin Oncol; 1983 Dec; 10(4 Suppl 4):20-4. PubMed ID: 6367051
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
[TBL] [Abstract][Full Text] [Related]
6. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
MacNeill FA; Jones AL; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1992 Oct; 66(4):692-7. PubMed ID: 1419608
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of androgen aromatization in human breast cancer.
Abul-Hajj YJ
J Steroid Biochem; 1980 Dec; 13(12):1395-400. PubMed ID: 7464118
[No Abstract] [Full Text] [Related]
8. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo.
Jacobs S; Lønning PE; Haynes B; Griggs L; Dowsett M
J Enzyme Inhib; 1991; 4(4):315-25. PubMed ID: 1669831
[TBL] [Abstract][Full Text] [Related]
9. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate SL
Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
[TBL] [Abstract][Full Text] [Related]
10. Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion.
Dowsett M; Mehta A; Cantwell BM; Harris AL
Eur J Cancer; 1991; 27(7):846-9. PubMed ID: 1657077
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
MacNeill FA; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
[TBL] [Abstract][Full Text] [Related]
12. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate S
Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
[TBL] [Abstract][Full Text] [Related]
13. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
14. Low-dose aminoglutethimide and aromatase inhibition.
Dowsett M; Jeffcoate SL; Santner S; Santen RJ; Stuart-Harris R; Smith IE
Lancet; 1985 Jan; 1(8421):175-6. PubMed ID: 2857259
[No Abstract] [Full Text] [Related]
15. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
16. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Samojlik E; Santen RJ; Kirschner MA; Ertel NH
Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
[TBL] [Abstract][Full Text] [Related]
18. Basic studies on aminoglutethimide.
Salhanick HA
Cancer Res; 1982 Aug; 42(8 Suppl):3315s-3321s. PubMed ID: 7083193
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
[TBL] [Abstract][Full Text] [Related]
20. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
Lønning PE; Dowsett M; Powles TJ
J Steroid Biochem; 1990 Mar; 35(3-4):355-66. PubMed ID: 2139151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
